Fully Human Antibodies, Acceleration of Discovery & Development
Mission
Individual Project Design, Fee for Service or Milestone-based
Contract Research, R&D Services
Partnered R&D, Collaborations, Licensing
Pipeline & Partnering
YUMAB® – Company
YUMAB is a world leading provider of contract research, technologies, and R&D services for the development of fully human, therapeutic antibodies. The YUMAB® platform is based on almost 30 years of continuous research by its founders in antibody discovery and engineering. It combines state of the art and next generation technologies from target to lead under one roof. YUMAB offers individually designed projects and business solutions for small biotech start-ups up to large biopharma companies.
News & Events
COVID-19: First step towards antibody therapy
March 25, 2020
Partnership of Boehringer Ingelheim and YUMAB yields in receptor blocking antibodies against SARS-CoV-2
Read more
Coronavirus statement
March 20, 2020
YUMAB is committed to uphold its business activities during times of the coronavirus pandemic.
Read more
Proteins & Antibodies Congress
April 27-29, 2020
Meet Philipp Kuhn to discuss your needs in antibody development and engineering.
Read more
Enleofen enters joint development with Boehringer Ingelheim
January 09, 2020
YUMAB partner Enleofen joins forces with Boehringer Ingelheim to develop novel anti-IL-11 therapies for a range of fibrotic diseases.
Read more
CRO / R&D Services
YUMAB offers contract research, technologies and R&D services for the discovery and development of fully human, therapeutic antibodies.
YUMAB® Platform, Partnering
YUMAB also provides partnering and collaboration strategies to provide access to our technologies and expertise for academic spin-offs and start-up companies without the burden of technology access fees.
Contact
SEND US AN E-MAIL
YUMAB GMBH
Phone: (+49) 531-481170-0
Email: info@yumab.com
YUMAB Inc.
1100 South Tower
225 Peachtree Street NE
Atlanta, GA 30303 – USA
Phone: (+49) 531 481170-0
Email: info@yumab.com
Phone: +49 531 481170-0
Fax: +49-531 481170-17